AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company.
– Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September
– Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD
– FDA Fast Track designation granted in July for ACI-35.030 (now “JNJ-2056”) for AD